24th week of 2010 patent applcation highlights part 55 |
Patent application number | Title | Published |
20100152084 | SOLUTIONS FOR OPHTHALMIC LENSES CONTAINING AT LEAST ONE SILICONE CONTAINING COMPONENT - The present invention relates to a method for reducing the occurrence of superficial punctate staining comprising the step of packaging, storing or contacting an uncoated ophthalmic lens comprising at least one polymeric wetting agent and polymer units derived from at least one silicone containing component in a solution comprising an osmolality of about 220 mOsm/kg or greater. | 2010-06-17 |
20100152085 | CLEANING SOLUTION FOR SEMICONDUCTOR DEVICE OR DISPLAY DEVICE, AND CLEANING METHOD - A cleaning solution for semiconductor devices or display devices containing a polyamine of a specified structure having two or more amino groups in adjacent positions of a carbon chain or a salt thereof and a cleaning method of semiconductor devices or display devices using the subject cleaning solution are provided. The cleaning solution for semiconductor devices or display devices of the present invention has high safety, brings a little burden on the environment and is able to easily remove etching residues on a semiconductor substrate in a short time; on that occasion, it is possible to achieve microfabrication without utterly corroding wiring materials; and furthermore, rinsing can be achieved with only water without necessity for use of, as a rinse solution, an organic solvent such as alcohols. In consequence, according to the cleaning method of the present invention, in manufacturing semiconductor devices or display devices, it is possible to extremely advantageously manufacture circuit wirings with a little burden on the environment, high precision and high quality on an industrial scale. | 2010-06-17 |
20100152086 | Wet Clean Compositions for CoWP and Porous Dielectrics - The present invention is a formulation for wet clean removal of post etch and ash residue from a semiconductor substrate having a CoWP feature, comprising;
| 2010-06-17 |
20100152087 | COMPOSITIONS AND METHODS COMPRISING A SUBTILISIN VARIANT - The present invention provides a subtilisin variant that is particularly well suited to cleaning applications. In particular, the present invention provides a | 2010-06-17 |
20100152088 | COMPOSITIONS AND METHODS COMPRISING A SUBTILISIN VARIANT - The present invention provides a | 2010-06-17 |
20100152089 | Liquid, Highly Foaming Detergent or Cleaning Agent with Stable Viscosity - Liquid washing or cleaning agent comprising a surfactant mixture having at least one anionic surfactant and an alkylpolyglucoside (APG), a foam booster, and an electrolyte, the ratio of anionic surfactant to electrolyte being higher than 10:1. Washing or cleaning agents of this kind are high-foaming and have a viscosity that permits the use thereof for hand laundering. | 2010-06-17 |
20100152090 | LIQUID DETERGENT COMPOSITION - The present invention relates to a liquid detergent composition containing (a) a specific compound having one alkyl group selected from a 2-ethylhexyl group, an isononyl group and an isodecyl group, (b) a surfactant selected from anionic surfactants and amphoteric surfactants, (c) a hydrophobic organic solvent that is liquid at 20° C., and (d) water in specific ratios. | 2010-06-17 |
20100152091 | CLEANING COMPOSITION - A neutral composition comprising an alkyl polyglucoside, a fatty alcohol polyglycol ether, xanthan gum, a biocide, and citric acid is disclosed which is useful for cleaning articles in need thereof. In exemplary embodiments the disclosed composition comprises an alkyl polyglucoside composition that is a mixture of C8/10 and C10/16 alkyl polyglucosides having an average degree of polymerization of about 1.5, a C12/16 fatty alcohol polyglycol ether 7 EO, xantham gum, a biocide composition comprising a mixture of isothiazolone compounds, and citric acid and has a pH of about 6.5-7.5. | 2010-06-17 |
20100152092 | SUBTILASES - The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent. | 2010-06-17 |
20100152093 | SOLVENT COMPOSITIONS COMPRISING UNSATURATED FLUORINATED HYDROCARBONS - This invention relates to cleaning compositions comprising unsaturated fluorinated hydrocarbons. The invention further relates to use of said cleaning compositions in methods to clean, degrease, deflux, dewater, and deposit fluorolubricant. The invention further relates to novel unsaturated fluorinated hydrocarbons and their use as cleaning compositions and in the methods listed above. | 2010-06-17 |
20100152094 | METHOD FOR FORMULATING ACTIVE FRAGRANCE INGREDIENTS IN ORDER TO PROTECT THEM AND INCREASE THEIR REMANENCE - The invention pertains to a new method for formulating active fragrance ingredients in such a way as to protect them and to slow the evaporation method of said active ingredients. It relies upon the use of thickening acrylic emulsions, at a pH above 5 and containing hydrophobic groups in order to trap said active ingredients. The invention also pertains to various methods of realizing the active ingredients thus formulated: a mixture in water of these active ingredients with thickening emulsions, dispersion of solid particles of these polymers and of these active ingredients after acidification, and solid particles obtained in a dry state after water is eliminated. Finally, the invention pertains to the use of these various formulations in order to protect an active ingredient and slow its evaporation kinetic. | 2010-06-17 |
20100152095 | Wound healing - A composition for use in the treatment of wounds to inhibit scar tissue formation during healing is disclosed, comprising an effective activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier. The method of preparation of said composition and method of administering the composition to a host suffering from tissue wounding is also disclosed. | 2010-06-17 |
20100152096 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF AMINO-SUBSTITUTED (E)-2, 6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES - Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. | 2010-06-17 |
20100152097 | POLYMER-BASED SUSTAINED RELEASE DEVICE - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 2010-06-17 |
20100152098 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF - Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism. | 2010-06-17 |
20100152099 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA - The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma. | 2010-06-17 |
20100152100 | ACCELERATED THERAPY - The present invention encompasses the surprising finding that romidepsin can safely be administered to humans on an accelerated dosing schedule. | 2010-06-17 |
20100152101 | TRIAZOL COMPOUNDS FOR TREATING BIOFILM FORMATION - The present invention relates to the use of a Compound of formula I | 2010-06-17 |
20100152102 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN - The invention primarily relates to the use of somatostatin or one of the agonistic analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve and, in particular, to reduce the depletion of the ovarian follicular reserve over time in non-menopausal women or to the use of an antagonistic analog of somatostatin for producing a medicament serving to accelerate the start of growing of quiescent follicles in non-menopausal women. The invention also relates to in vitro applications of somatostatin and of agonistic and antagonistic analogs thereof. | 2010-06-17 |
20100152103 | 4-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUES, INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I | 2010-06-17 |
20100152104 | Methods for Inhibiting Growth of Prolactin-Responsive Cancer Cells with Cyclosporine A or Other Cyclophilin Inhibitors - Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin. | 2010-06-17 |
20100152105 | USE OF RAPAMYCIN DERIVATIVES IN CHRONIC REJECTION - The present invention is directed to the use of a rapamycin derivative of formula I in combination with cyclosporin for preventing or treating manifestations of chronic rejection in a recipient of an organ or tissue transplant. | 2010-06-17 |
20100152106 | AGENT FOR THERAPY AND/OR IMPROVEMENT OF DISSEMINATED INTRAVASCULAR COAGULATION - It is an object of the present invention to provide a therapeutically effective agent for therapy and/or improvement of DIC, or a method for treating and/or improving DIC. The present invention provides an agent for therapy and/or improvement of disseminated intravascular coagulation comprising thrombomodulin as an active ingredient, which is administered to antithrombin-reduced patients having a low plasma antithrombin activity of less than 50%. | 2010-06-17 |
20100152107 | LONG-TERM FEED - CANCER PATIENT - Pursuant to the present invention, methods and compositions are provided for providing long-term tube-fed nutrition. More specifically, pursuant to the present invention, methods and compositions are provided for providing long-term tube-fed nutrition to cancer patients. | 2010-06-17 |
20100152108 | METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE - The invention provides methods and combination therapies for treating and/or preventing and/or slowing the onset and/or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable salt thereof or therapy for Alzheimer's disease. | 2010-06-17 |
20100152109 | Influenza inhibiting compositions and methods - The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR. | 2010-06-17 |
20100152110 | ALTERNATE READING FRAME POLYPEPTIDES DERIVED FROM HEPATITIS C AND METHODS OF THEIR USE - Novel hepatitis C virus (HCV) polypeptides are provided which are not encoded by the standard HCV open reading frame. These alternate reading frame polypeptides are useful, inter alia, in vaccine compositions, in diagnosing HCV infection, and as therapeutic targets. | 2010-06-17 |
20100152111 | Polymer-based sustained release device - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 2010-06-17 |
20100152112 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives. | 2010-06-17 |
20100152113 | METAL-BINDING THERAPEUTIC PEPTIDES - The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes. | 2010-06-17 |
20100152114 | Antioxidant activity of GH-RH Antagonists - There are provided means for suppressing the Reactive Oxidant Species (ROS) of certain cells by the administration of GHRH antagonists. The therapeutic applications of the anti-oxidative action of GH-RH antagonists relate to the redox status of certain cells, including but not limited to cancer cells, reducing the metabolism of reactive oxygen and nitrogen species. This antioxidant activity of GHRH antagonists is employable in the treatment of diseases in which their pathogenesis is related to increased cellular level of oxidative stress. | 2010-06-17 |
20100152115 | DETECTION OF PHYSIOLOGICALLY ACCEPTABLE POLYMER MOLECULES USING NEAR INFRARED SPECTROSCOPY - The present invention relates, in general, to methods for detecting the amount of a polymer on a protein using near-infrared spectroscopy. Measurement of the number of polymer moieties per protein molecule allows for production of molecules having a uniform number of polymer moieties, which is useful in the production of pharmaceutical compositions. | 2010-06-17 |
20100152116 | Treatment of amyotrophic lateral sclerosis - The present invention relates to the treatment of motoneuron diseases. More particularly, the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a pre-clinical ALS animal model induces a significant motor performance and prolongation of survival time of the animals. | 2010-06-17 |
20100152117 | Aequorin-Containing Compositions and Methods of Using Same - Compositions containing aequorin and methods for their use in preventing and/or alleviating symptoms and disorders related to calcium imbalance are provided by the present invention. | 2010-06-17 |
20100152118 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES - This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases. | 2010-06-17 |
20100152119 | PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING PEPTIDES - The present invention concerns the use of peptide fragments of the protein SLC24A5 as active agents designed to induce, increase, or restore the synthesis of melanin in the melanocytes of the epidermis or of the pilar bulb, alone or in association with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical or particularly dermatological composition. The invention is also related to any composition containing the active agents. | 2010-06-17 |
20100152120 | METHODS AND APPARATUS FOR THE ENHANCED DELIVERY OF PHYSIOLOGIC AGENTS TO TISSUE SURFACES - Apparatus and methods deliver physiologically active agents in the presence of adjuvant gases. The adjuvant gases can enhance the effectiveness of the drug, lower the dosage of drug or concentration of drug necessary to achieve a therapeutic result, or both. Exemplary adjuvant gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases. | 2010-06-17 |
20100152121 | Iodo-Hexose Compounds Useful to Treat Cancer - Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a iodo-hexose compound to a subject in need thereof. The subject disclosure includes methods of treating glioblastoma and pancreatic cancer comprising the administration of a therapeutically effective amount of a 2-deoxy-2-iodo-D-hexose compound including 2-deoxy-2-iodo-D-mannose, 2-deoxy-2-iodo-D-glucose, 2-deoxy-2-iodo-D-galactose, and/or 2-deoxy-2-iodo-D-talose to a subject in need thereof. | 2010-06-17 |
20100152122 | OLIGO-GULURONATE AND GALACTURONATE COMPOSITIONS - The invention provides a pharmaceutical composition comprising a macromolecular drug and an oligoguluronate or oligogalacturonate, e.g., having a number average degree of polymerization in the range 5 to 18, a guluronate (or galacturonate) fraction (F | 2010-06-17 |
20100152123 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS CAUSED BY A DEFICIENCY IN A GENE PRODUCT OF A CLN GENE - The present invention provides methods and compositions for treating a disorder associated with a deficiency in a gene product of a CLN gene in a subject (e.g., neuronal ceroid lipofuscinosis (NCL)), comprising administering to the subject an effective amount of a sphingolipid (e.g., galactosylceramide, ceramide, lysophosphatidic acid, sulfatide and any combination thereof), thereby treating the disorder in the subject. | 2010-06-17 |
20100152124 | USE OF HEDERAGENIN 3-0 ALPHA-L-RHAMNOPYRANOSYL(1-2)-(BETA-D-GLUCOPYRANOSYL(1-4)-ALPHA-L-ARABINOP- YRANOSIDE OR AN EXTRACT FROM PULSATILLAE RADIX CONTAINING THE SAME AS A THERAPEUTIC AGENT FOR SOLID TUMORS - This invention relates to a use of hederagenin 3-O-α-L-rhamnopyranosyl((1→2)-[β-D-glucopyranosyl(1→4)]-α-L-arabinopyranoside or a Pulsatillae radix extract containing the same as a therapeutic agent for solid tumors. Also, this invention relates to a method of preparing a therapeutic agent for solid tumors by using hederagenin 3-O-α-L-rhamnopyranosyl(1→2)-[β-D-glucopyranosyl(1→4)]-α-L-arabinopyranoside, or a method of treating a subject suffering from solid tumors, comprising administering to the subject a therapeutically effective dose of hederagenin 3-O-α-L-rhamnopyranosyl(1→2)-[β-D-glucopyranosyl(1→4)]-α-L-arabinopyranoside. | 2010-06-17 |
20100152125 | Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases - One aspect of the invention relates to a method of treating or preventing a neurodegenerative disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an inhibitor of the formation of advanced glycation end products. Another aspect of the invention relates to a proteasome activity-based screening assay to select compounds which may be useful for treating or preventing a neurodegenerative disease, and the materials used therein. Yet another aspect of the invention relates to molecules, and methods of use thereof, which bind at or adjacent to SOD-I Trp32, including molecules that bind in a site adjacent to SOD-I Trp32 whether or not it is oxidized, for treating or preventing neurodegenerative disease. | 2010-06-17 |
20100152126 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B - This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: | 2010-06-17 |
20100152127 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF - The invention provides compounds having the following general formula (I): | 2010-06-17 |
20100152128 | Antiviral Agents - A compound of formula (I) and pharmaceutically acceptable salts thereof; compositions containing it and its use in medicine, particularly for the treatment or inhibition of HCV infections, and processes for making it are disclosed. | 2010-06-17 |
20100152129 | Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer - Synergistic combinations of gemcitabine with P276-00 or P1446A and their use in the treatment of cancer are disclosed. The invention further describes novel and unique gene signatures comprising gene markers used to monitor the drug response in a subject treated with the said combinations. | 2010-06-17 |
20100152130 | TREATMENT OF CANCER WITH GLUTAMINE - Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine. | 2010-06-17 |
20100152131 | METHOD FOR PRODUCING PURIFIED HEMATINIC IRON-SACCHARADIC COMPLEX AND PRODUCT PRODUCED - A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals. | 2010-06-17 |
20100152132 | Use of a Composition Comprising an Antacid, a Mucolytic and a Gelling Agent in the Treatment of Cold - The present invention is concerning a medicine to alleviate and cure colds h} reduced acid content and stimulation of increased mucus production through the fact that active components of the substance consist of acid stanching components like proton p<2010-06-17 | |
20100152133 | USE OF CHITOSANS TO INCREASE NAIL GROWTH RATE - The present invention is directed to the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, to increase nail growth rate. The invention is further directed to the use of chitosans to accelerate nail growth rate during treatment of nail illnesses, nail dystrophy or other nail conditions, in order to shorten considerably the specific treatments of said nail illnesses, nail dystrophy or other nail conditions. | 2010-06-17 |
20100152134 | EMULSIFIED SKIN EXTERNAL PREPARATION AND METHOD FOR STABILIZING THE SKIN EXTERNAL PREPARATION - An emulsified skin external preparation containing a tocopherol glycinate derivative has excellent storage stability without viscosity reduction during storage. The emulsified skin external preparation includes 0.03 to 25% by mass of a tocopherol glycinate derivative, and 0.05 to 25% by mass of at least one fatty acid ester selected from the group consisting of glycerin mono fatty acid ester, polyglycerin fatty acid ester and dextrin fatty acid ester, the tocopherol glycinate derivative being represented by Formula (1): . . . (1) wherein R | 2010-06-17 |
20100152135 | COSMETIC KIT COMPRISING REACTIVE SILICONE COMPOUNDS AND A GLOSSY OIL - The invention relates to a cosmetic kit comprising at least two separately-packaged cosmetic compositions, -the kit comprising at least one silicone compound X, at least one silicone compound Y and, optionally, at least one catalyst, -with the proviso that the compounds X and Y—and the catalyst when present—are not simultaneously in one of said compositions, -said compounds X and Y being able to react together by a hydrosilylation reaction when the catalyst is present or by condensation reaction, when they are brought into contact with one another, -one at least of the first and second compositions comprising at least one glossy oil, -said compounds X and Y and said glossy oil, and their respective amounts, being such that the average gloss of the deposit comprising the two compositions is greater than or equal to 60 out of 100. Lastly the invention relates to a method of making-up keratin materials that involves applying the compounds X and Y and the glossy oil. | 2010-06-17 |
20100152136 | TP53 Gene expression and uses thereof - The present invention is drawn to diagnosis, prognosis and treatment of multiple myeloma. In this regard, the present invention discloses importance of down-regulation of TP3 gene in multiple myeloma and its use as an independent progostic indicator of multiple myeloma. Additionally, the present invention also discloses novel-TP53 associated genes and demonstrates the clinical relevance of these alterations to disease progression. | 2010-06-17 |
20100152137 | Alkylphospholipids as active agents for prevention of plant pathogens - The invention relates to a process for controlling plant pathogens comprising the application of alkylphospholipids as active substances. Further, the invention relates to the use of alkylphospholipids for controlling plant pathogens, and to an agent for controlling plant pathogens containing an effective amount of at least one alkylphospholipid. | 2010-06-17 |
20100152138 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT - Disclosed are compounds of the formula | 2010-06-17 |
20100152139 | EMULSIFIED SKIN EXTERNAL PREPARATION AND METHOD FOR STABILIZING THE SKIN EXTERNAL PREPARATION - An emulsified skin external preparation containing a salt of a higher fatty acid ester of ascorbic acid-2-phosphate is provided, and the decomposition and consequent decrease of the salt are prevented and thereby the stability of the preparation is enhanced. A method for stabilizing the skin external preparation containing a salt of a higher fatty acid ester of ascorbic acid-2-phosphate is provided. The emulsified skin external preparation includes 0.03 to 25% by mass of a salt of a higher fatty acid ester of ascorbic acid-2-phosphate (A), and 0.05 to 25% by mass of a glycerin mono fatty acid ester (B), the higher fatty acid ester of ascorbic acid-2-phosphate being represented by Formula (1): . . . (1) wherein R is a higher fatty acid residue. | 2010-06-17 |
20100152140 | Method of Cancer Treatment with Naphthol Analogs - In one embodiment, the present invention relates to a method of treating a cancer characterized by overexpression of cyclic adenosine monophosphate response element-binding protein (CREB) or phosphorylated CREB (p-CREB) by administering to a patient suffering from the cancer a pharmaceutically-effective amount of a composition comprising a compound selected from the group consisting of 2-{1-[3-(Amidinothio)propyl]-1H-indol-3-yl}-3-(1-methylindol-3-yl)maleimide, naphthol analogs having the structure (I), wherein R | 2010-06-17 |
20100152141 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS - The invention relates to 5-HT | 2010-06-17 |
20100152142 | CRYSTALLINE FORM II OF TIGECYCLINE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides processes for the preparation of crystalline forms of Tigecycline. | 2010-06-17 |
20100152143 | Methods of Treating Skin Disorders with Caffeic Acid Analogs - Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%. | 2010-06-17 |
20100152144 | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease - A method for preventing or treating vascular hyperreactivity in which a chemical compound that is an estrogen beta receptor agonist is administered to a subject suffering from or at risk of vascular hyperreactivity. Preferably, the administration is topically to the skin. | 2010-06-17 |
20100152146 | Topical Administration of Danazol - Pharmaceutical preparations for topical or local administration of drugs directly to the skin for treatment of disorders of the subcutaneous fatty tissue, in particular in cases of cellulite, are disclosed herein. In a preferred embodiment, the drug is danazol or gastrinone. In another embodiment, the drug is danazol in combination with an aromatase inhibitor or an estrogen compound. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion, ointment, gel or emulsion, solution or foam. | 2010-06-17 |
20100152147 | Compositions Comprising Azelastine and Methods of Use Thereof - The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride, particularly wherein the compositions are provided in unit dosage form. In certain embodiments, the invention provides such unit dosage pharmaceutical compositions comprising azelastine hydrochloride formulated for use as nasal sprays and/or ocular solutions or drops. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of a variety of allergic and non-allergic conditions, particularly conjunctivitis, sinusitis, rhinitis and rhinosinusitis. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance. | 2010-06-17 |
20100152148 | NOVEL COMPOUNDS - A compound of formula (I): | 2010-06-17 |
20100152149 | Formulation - The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle. | 2010-06-17 |
20100152150 | THE APPLICATION OF MARINE STEROID IN PREPARING THE MEDICINE OF TREATING NEURONS DAMAGING - The application of marine steroid, i.e. 24-methylene-cholest-3β,5α,6β,19-tetrol, in preparing the medicine of treating neurons damaging is provided in the present invention. The keto-sterols compounds marine steroid YC-1 extracted from | 2010-06-17 |
20100152151 | TGR5 MODULATORS AND METHODS OF USE THEROF - The invention relates to compounds of Formula A: | 2010-06-17 |
20100152152 | Therapeutic Use of Nefopam - Nefopam is used for the manufacture of a medicament for the treatment of an affective disorder such as ADD or ADHD. | 2010-06-17 |
20100152153 | Nitric Oxide Releasing Compounds - Compositions comprising nitrosyl-cobinamide are provided. Also provided are methods for treating hypertension, which comprise administering therapeutically effective amounts of nitrosyl-cobinamide. Also provided are methods for producing nitrosyl-cobinamide. | 2010-06-17 |
20100152154 | NOVEL PLATINUM COMPOUNDS FOR TREATING CANCER - A series of platinum compounds and methods of treating cancer by said platinum compounds are disclosed. | 2010-06-17 |
20100152155 | Histone Deacetylase Inhibitors - Compounds of formula: (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: (I) wherein Q, V and W independently represent —N═ or —C═; B is a divalent radical selected from: (IIA), (IIB), (IIC), (IID), and (IIE). Wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; and -[Linker1]- and -[Linker2]- independently represent a bond, or a divalent linker radical. | 2010-06-17 |
20100152156 | 2-Azetidinone Derivatives For The Treatment Of Hyperlipidaemic Diseases - The invention relates to novel 2-azetidinone derivatives of formula (I) and to pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds are cholesterol absorption inhibitors, useful in the treatment of hyperlipidaemic conditions. The invention also relates to processes for their manufacture and to pharmaceutical compositions containing them. | 2010-06-17 |
20100152157 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF - The invention relates to the 6-cycloamino-3-(pyridazin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): | 2010-06-17 |
20100152158 | Substituted Disulfonamide Compounds - Substituted disulfonamide compounds corresponding to formula I: | 2010-06-17 |
20100152159 | IMIDAZOPYRAZINE SYK INHIBITORS - Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample. | 2010-06-17 |
20100152160 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS - The present invention relates to benzodioxane and benzoxazine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 2010-06-17 |
20100152161 | COMPOSITIONS FOR WEIGHT MANAGEMENT - Methods and compositions for preventing or reducing weight gain associated with drug treatment, which utilize an H | 2010-06-17 |
20100152162 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER - It is intended to provide an agent for treating and/or preventing sleep disorder containing as an active ingredient a thiazole derivative represented by the general formula (I) (in the formula, R | 2010-06-17 |
20100152163 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE - This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1,2,3,4,5,6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided. | 2010-06-17 |
20100152164 | Method For Stabilizing Anti-Dementia Drug - The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug. | 2010-06-17 |
20100152165 | CARBOXYLIC ACID DERIVATIVES - [Problem] To provide a pharmaceutical, particularly a compound which can be used as an insulin secretion promoter or a preventive or therapeutic agent for diabetes mellitus and the like diseases in which GPR40 is concerned. | 2010-06-17 |
20100152166 | COMPOUNDS AND METHODS FOR MODULATING FXR - Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia. | 2010-06-17 |
20100152167 | PYRIMIDINE DERIVATIVES - The present invention relates to trisubstituted pyrimidines of formula (I) | 2010-06-17 |
20100152168 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE - The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R | 2010-06-17 |
20100152169 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES - The invention concerns a compound of the Formula (I) wherein m is 1-2 and each R | 2010-06-17 |
20100152170 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors - The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention. | 2010-06-17 |
20100152171 | CGRP Antagonists - CGRP antagonists of the formula | 2010-06-17 |
20100152172 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES - The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases. | 2010-06-17 |
20100152173 | Tablet Having Improved Stability With At Least Two Actives - The present invention relates to a tablet comprising at least a first and second active, the first active being in the form of a non-aqueous granulate, the second active ingredient being in the form of melt extrudated granules or a granulate (aqueous or non-aqueous). The first and second active forms are blended together. The present invention is further directed to a method of producing said tablet. | 2010-06-17 |
20100152174 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI - The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH; Y represents —C | 2010-06-17 |
20100152175 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders - There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: | 2010-06-17 |
20100152176 | Modulators of Muscarinic Receptors - The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases. | 2010-06-17 |
20100152177 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY - The present disclosure provides compounds having affinity for the 5HT6 receptor which are of the formula (I): | 2010-06-17 |
20100152178 | IMIDAZOLE DERIVATIVES - A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): | 2010-06-17 |
20100152179 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity. | 2010-06-17 |
20100152180 | 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) - The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment. | 2010-06-17 |
20100152181 | AMINO PYRAZOLE COMPOUND - The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias. | 2010-06-17 |
20100152182 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors - Disclosed are pyrimidine derivatives of formula | 2010-06-17 |
20100152183 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein. | 2010-06-17 |
20100152184 | PHARMACEUTICAL COMPOUNDS - The invention provides a compound for use in medicine, the compound being a compound of the formula (VI | 2010-06-17 |